Lyell Immunopharma, Inc.
LYEL Healthcare Biotechnology
Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024. In the quarter to June 2026, revenue fell 50.0%, EPS grew 33.6% and free cash flow grew 1.31%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow LYEL
Lyell Immunopharma, Inc. (LYEL) EV/Sales
As of 16 October 2026, Lyell Immunopharma, Inc. (LYEL) trades at a EV/Sales of −550×. Over the past ten years it has ranged from −4,572× (December 2024) to 9,403× (December 2025); the current reading is higher than 25% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7,747× | — |
| FY2024 | −3,331× | — |
| FY2023 | −128× | — |
| FY2022 | 2.2× | (94.53%) |
| FY2021 | 41.1× | — |
| FY2020 | −39.7× | — |
| FY2019 | −39.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4,599× | (22.86%) |
| Mar 2026 | 5,962× | (23.05%) |
| Dec 2025 | 7,747× | — |
| Sep 2025 | −560× | — |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LYEL Lyell Immunopharma, Inc. | −550× |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | 0.5× |
| IVVD Invivyd, Inc. compare | 0.7× |
| CGEN Compugen Ltd. compare | 0.8× |
| PRQR ProQR Therapeutics N.V. compare | 0.9× |
| NAGE Niagen Bioscience, Inc. compare | 1.0× |
| ADCT ADC Therapeutics SA compare | 1.5× |
| RNAC Cartesian Therapeutics, Inc. compare | 56.5× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)